Temozolomide responsiveness in aggressive corticotroph tumours: A case report and review of the literature

Pituitary

Volumn 15, Issue 3, 2012, Pages 276-287

  Annamalai, A K ^a   Dean, A F ^b   Kandasamy, N ^a   Kovacs, K ^c   Burton, H ^a   Halsall, D J ^b   Shaw, A S ^b   Antoun, N M ^b   Cheow, H K ^b   Kirollos, R W ^b   Pickard, J D ^b   Simpson, H L ^a   Jefferies, S J ^b   Burnet, N G ^d   Gurnell, M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Hepatic metastases; MGMT; Pituitary corticotroph adenoma carcinoma; Temozolomide

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CORTICOTROPIN; DESMOPRESSIN; ETOPOSIDE; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; HYDROCORTISONE; KETOCONAZOLE; LEVOTHYROXINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METYRAPONE; OCTREOTIDE; PASIREOTIDE; TEMOZOLOMIDE; TESTOSTERONE;

ACTH SECRETING ADENOMA; ADRENALECTOMY; AGED; CANCER RESISTANCE; CASE REPORT; CUSHING SYNDROME; DRUG RESPONSE; HUMAN; HYPERCORTISOLISM; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; LIVER NEOPLASMS; MALE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PITUITARY NEOPLASMS;

EID: 84867404409     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0363-7     Document Type: Review

References (71)

1. Kaltsas GA, Grossman AB (1998) Malignant pituitary tumours. Pituitary 1(1):69-81
2. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90(5):3089-3099
3. Lopes MB, Scheithauer BW, Schiff D (2005) Pituitary carcinoma: diagnosis and treatment. Endocrine 28(1):115-121
4. Pernicone P, Scheithauer B, Sebo T, Kovacs K, Horvath E, Young WJ, Lloyd R, Davis D, Guthrie B, Schoene W (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79(4):804-812
5. Ragel B, Couldwell W (2004) Pituitary carcinoma: a review of the literature. Neurosurg Focus 16(4):E7
6. van der Klaauw A, Kienitz T, Strasburger C, Smit J, Romijn J (2009) Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature. Pituitary 12(1):57-69
7. Landman R, Horwith M, Peterson R, Khandji A, Wardlaw S (2002) Long-term survival with ACTH-secreting carcinoma of the pituitary: a case report and review of the literature. J Clin Endocrinol Metab 87(7):3084-3089
8. George DH, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr, Lloyd RV, Meyer FB (2003) Crooke's cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 27(10):1330-1336
9. Holthouse D, Robbins P, Kahler R, Knuckey N, Pullan P (2001) Corticotroph pituitary carcinoma: case report and literature review. Endocr Pathol 12(3):329-341
10. Roncaroli F, Faustini-Fustini M, Mauri F, Asioli S, Frank G (2002) Crooke's hyalinization in silent corticotroph adenoma: report of two cases. Endocr Pathol 13(3):245-249
11. Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF Jr, Lloyd RV (2005) Pituitary carcinoma: a clinicopathological review. Neurosurgery 56(5):1066-1074. Discussion 1066-1074
12. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP (2006) Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 7(6):518-520
13. Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Simmons NE (2006) Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 105(4):621-626
14. Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E, Kovacs K (2006) Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65(4):552-553
15. Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu JJ, Tischler AS, Lechan RM (2007) Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10(1):81-86
16. Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE (2007) Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 38(1):185-189
17. Moyes VJ, Alusi G, Sabin HI, Evanson J, Berney DM, Kovacs K, Monson JP, Plowman PN, Drake WM (2009) Treatment of Nelson's syndrome with temozolomide. Eur J Endocrinol 160(1):115-119
18. McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG, Clifton-Bligh RJ (2009) Low O6-methylguanine- DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 71(2):226-233
19. Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Horvath E, Rotondo F, Kovacs K (2009) Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. Hormones (Athens) 8(4):303-306
20. Takeshita A, Inoshita N, Taguchi M, Okuda C, Fukuhara N, Oyama K, Ohashi K, Sano T, Takeuchi Y, Yamada S (2009) High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease. Eur J Endocrinol 161(4):553-559
21. Hagen C, Schroeder HD, Hansen S, Andersen M (2009) Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 161(4):631-637
22. Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD (2009) Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery 64(4):E773-E774 Discussion E774
23. Byrne S, Karapetis C, Vrodos N (2009) A novel use of temozolomide in a patient with malignant prolactinoma. J Clin Neurosci 16(12):1694-1696
24. Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes HP, Thomé C (2010) SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes 118(10):760-763
25. Morin E, Berthelet F, Weisnagel J, Bidlingmaier M, Serri O (2010) Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary. doi:10.1007/s11102-010-0232-9
26. Mohammed S, Cusimano MD, Scheithauer BW, Rotondo F, Horvath E, Kovacs K (2010) O-methylguanine-DNA methyltransferase immunoexpression in a double pituitary adenoma: case report. Neurosurgery 66(2):E421-E422. Discussion E422
27. Guzel A, Tatli M, Senturk S, Guzel E, Cayli SR, Sav A (2008) Pituitary carcinoma presenting with multiple metastases: case report. J Child Neurol 23(12):1467-1471
28. Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC (2008) MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115(2):261-262
29. Dillard TH, Gultekin SH, Delashaw JB, Yedinak CG, Neuwelt EA, Fleseriu M (2011) Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary 14(1):80-91
30. Curto L, Torre ML, Ferrau F, Pitini V, Altavilla G, Granata F, Longo M, Hofland LJ, Trimarchi F, Cannavo S (2010) Temozolomide- induced shrinkage of a pituitary carcinoma causing Cushing's disease-report of a case and literature review. Sci World J 10:2132-2138
31. Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P, Reni M (2010) Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 163(6):843-851
32. Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K (2011) Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy. Hormones (Athens) 10(2):162-167
33. Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Chazot F, Honnorat J, Trouillas J, Raverot G (2011) New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary. doi:10.1007/s11102-011-0341-0
34. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, François P, Jouanneau E, Passagia JG, Bernier M, Cornélius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95(10):4592-4599
35. Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA, Vance ML, Thorner MO, Laws ER, Lopes MB (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95(11):E280-E290
36. Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y, Fine RL (2011) Temozolomide (Temodar-) and capecitabine (Xeloda-) treatment of an aggressive corticotroph pituitary tumor. Pituitary 14(4):418-424
37. Stupp R, Gander M, Leyvraz S, Newlands E (2001) Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2(9):552-560
38. Neidle S, Thurston DE (2005) Chemical approaches to the discovery and development of cancer therapies. Nat Rev Cancer 5(4):285-296
39. Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4(4):296-307
40. Chinot OL, Barrié M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM, Dufour H, Figarella-Branger D (2007) Correlation between O6-methylguanine- DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 25(12):1470-1475
41. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997-1003
42. Verbeek B, Southgate TD, Gilham DE, Margison GP (2008) O6- Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull 85:17-33
43. Netta L, Iris L, Bracha Z, Dana F, Felix B, Yakov F, Tali S (2006) Progressive low-grade oligodendrogliomas. Cancer 106(8):1759-1765
44. Maria M, Marietta W, Jörg F, Collins VP, Guido R (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113(3):379-385
45. Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL (2006) O6-Methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol 24(21):3431-3437
46. Widhalm G, Wolfsberger S, Preusser M, Woehrer A, Kotter MR, Czech T, Marosi C, Knosp E (2009) O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? Cancer 115(5):1070-1080
47. Fealey ME, Scheithauer BW, Horvath E, Erickson D, Kovacs K, McLendon R, Lloyd RV (2010) MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications. Endocr Pathol 21(3):161-165
48. Lau Q, Scheithauer B, Kovacs K, Horvath E, Syro LV, Lloyd R (2010) MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary 13(4):367-379
49. Salehi F, Scheithauer BW, Moyes VJ, Drake WM, Syro LV, Manoranjan B, Sharma S, Horvath E, Kovacs K (2010) Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome. Endocr Pathol 21(4):227-229
50. McCormack AI, Wass JA, Grossman AB (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 41(10):1133-1148. doi: 10.1111/j.1365-2362.2011.02520.x
51. Buchfelder M (2009) Management of aggressive pituitary adenomas: current treatment strategies. Pituitary 12(3):256-260
52. Kovacs K, Diep CC, Horvath E, Cusimano M, Smyth H, Lombardero CC, Scheithauer BW, Lloyd RV (2005) Prognostic indicators in an aggressive pituitary Crooke's cell adenoma. Can J Neurol Sci 32(4):540-545
53. Blevins LS, Sanai N, Kunwar S, Devin JK (2009) An approach to the management of patients with residual Cushing's disease. J Neurooncol 94(3):313-319
54. Barber TM, Adams E, Ansorge O, Byrne JV, Karavitaki N, Wass JA (2010) Nelson's syndrome. Eur J Endocrinol 163(4):495-507
55. Scheithauer BW, Horvath E,Abel TW, RobitalY, Park SH, Osamura RY,Deal C, Lloyd RV,Kovacs K(2011) Pituitary blastoma: a unique embryonal tumor. Pituitary. doi:10.1007/s11102-011-0328-x
56. Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K, Ishida Y, Takano K, Okinaga H, Matsuno A (2011) A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurgery 68(6):E1761-E1767 Discussion E1767
57. Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, Uribe H, Cusimano M, Kovacs K, Horvath E (2011) Treatment of pituitary neoplasms with temozolomide: a review. Cancer 117(3):454-462. doi:10.1002/cncr.25413
58. Kato Y, Okollie B, Raman V, Vesuna F, Zhao M, Baker SD, Bhujwalla ZM, Artemov D (2007) Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biol Ther 6(6):891-897
59. Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, Ghimenton C, Turazzi S, Talacchi A, Skrap M, Marucci G, Volpin L, Morandi L, Pizzolitto S, Gardiman M, Andreoli A, Calbucci F, Ermani M (2010) O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro Oncol 12(3):283-288
60. Weller M (2010) Temozolomide and MGMT forever? Neuro Oncol 12(3):219-220
61. Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, Dong SM, Nam DH (2010) Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 12(3):289-296
62. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W (2007) Efficacy and Tolerability of Temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25(22):3357-3361
63. Wick A, Pascher C, Wick W, Jauch T, Weller M, Bogdahn U, Hau P (2009) Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 256(5):734-741
64. Fukushima T, Takeshima H, Kataoka H (2009) Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res 29(11):4845-4854
65. Plowman J, Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD, Grever MR (1994) Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1- nitrosourea. Cancer Res 54(14):3793-3799
66. Narayana A, Golfinos JG, Fischer I, Raza S, Kelly P, Parker E, Knopp EA, Medabalmi P, Zagzag D, Eagan P, Gruber ML (2008) Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 72(2):383-389.
67. Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE, Rotondo F, Horvath E, Kovacs K (2011) Anti-VEGF therapy in pituitary carcinoma. Pituitary. doi:10.1007/s11102-011-0346-8
68. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C, Edkins S, Bignell G, Davies H, O'Meara S, Parker A, Avis T, Barthorpe S, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Richardson D, Shepherd R, Small A, Solomon H, Tofts C, Varian J, West S, Widaa S, Yates A, Easton DF, Riggins G, Roy JE, Levine KK, Mueller W, Batchelor TT, Louis DN, Stratton MR, Futreal PA, Wooster R (2006) A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66(8):3987-3991
69. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ, Louis DN (2007) Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13(7):2038-2045
70. Umar A, Koi M, Risinger JI, Glaab WE, Tindall KR, Kolodner RD, Boland CR, Barrett JC, Kunkel TA (1997) Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res 57(18):3949-3955
71. Liu L, Markowitz S, Gerson SL (1996) Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1, 3-bis(2-chloroethyl)nitrosourea. Cancer Res 56(23):5375-5379